Correlative Biomarkers of Response to Venetoclax (VEN) in Combination with Chemotherapy or Hypomethylating Agents (Hma) in Elderly Untreated Patients with Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Chyla, B. [1 ]
Popovic, R. [1 ]
Potluri, J. [1 ]
Hayslip, J. [1 ]
Huang, X. [1 ]
Mabry, M. [1 ]
Bhathena, A. [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
94
引用
收藏
页码：S84 / S85
页数：2
相关论文
共 50 条
  • [1] Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia
    Chyla, Brenda
    Popovic, Relja
    Potluri, Jalaja
    Hayslip, John
    Huang, Xin
    Zhu, Ming
    Mabry, Mack
    Bhathena, Anahita
    [J]. BLOOD, 2016, 128 (22)
  • [2] Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States
    Vachhani, Pankit
    Abbas, Jonathan A.
    Flahavan, Evelyn M.
    Ma, Esprit
    Xu, Tao
    Jin, Huan
    Montez, Melissa
    Huang, Weize
    Gershon, Anda
    Ku, Grace
    Flores, Brannon
    Onishi, Maika
    Bui, Cat N.
    Donnellan, William
    [J]. BLOOD, 2021, 138
  • [3] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    [J]. BLOOD, 2021, 138
  • [4] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [5] Intensive Induction Chemotherapy Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva Johanna
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony Selwyn
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian J.
    Stahl, Maximilian
    [J]. BLOOD, 2023, 142
  • [6] Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study
    Zhang, Jian
    Song, Baoquan
    Liu, Yin
    Wu, De-Pei
    Qiu, Huiying
    [J]. BLOOD, 2023, 142
  • [7] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    [J]. BLOOD, 2022, 140 : 6158 - 6159
  • [8] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [9] Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies
    Pollyea, Daniel A.
    Stevens, Brett M.
    Winters, Amanda
    Minhajuddin, Mohd
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Smith, Clayton
    Abbott, Diana
    Jordan, Craig T.
    [J]. BLOOD, 2017, 130
  • [10] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
    Khan, Hina
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Rios, Adan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
12345